Dr. Yang is mainly engaged in drug regulatory sciences and top-level design of drug policies and systems, and research on optimization of regulatory pathways and procedures. She is also interested in research on new tools, standards and methods for evaluating the safety, efficacy and quality of novel drugs, generic drugs (biosimilars), and drugs for rare diseases. The research scope covers the whole life cycle of drugs. Since joining Tsinghua University in October 2020, she has led 32 programs for the National Medical Products Administration (NMPA), Bill & Melinda Gates Foundation, Hainan Medical Products Administration, Guangdong Medical Administration, Industry associations, and top domestic and international pharmaceutical companies. During the period, she has published 10 SCI papers and 32 papers in core Chinese journals of Peking University as corresponding author.

Her representative books include "Research On Drug Regulatory Science of United States", " Navigation of Drug Marketing Application Holder System", "Research and Application of WHO Essential Drug System". She has edited the book "Reform of Pharmaceutical Raw Materials and Packaging Materials Related Review", "Reform and Innovation of Drug Clinical Trial Dynamic Management", "21st Century Cures Act", "FDA Responsibilities and Powers", etc.

Dr. Yang has conducted in-depth research on the theory and scientific logic of regulatory science, and has developed a unique system of research and methodology of reflection. She has established a basic research framework of systems, pathways, procedures, regulatory science tools, standards and methods, and proposed that drug regulatory science is based on comparative decision-making. She is also interested in drug administration policy and legislation, and participated as a core expert in the formulation and revision of the“Drug Administration Law of the People's Republic of China”and“Vaccine Administration Law of the People’s Republic of China”. She has served as an expert in the validation and consultation of the drug marketing authorization holder (MAH) system, the Patent linkage system, the Patent compensation system, the drug Data exclusivity system, the registration and incentive of rare disease drug R&D, and the reform of the biologics registration and classification system.